Compare Quest Diagnostics Inc (DGX) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Zeta Global Holdings Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: Quest Diagnostics Inc is far larger — about 3.1× Zeta Global Holdings Corp's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Zeta Global Holdings Corp for 19 Days on average.
| DGX | ZETA | |
|---|---|---|
Market Cap | $25.48B | $8.29B |
Volume | 941,866 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $247.45 | $33.74 |
52-Week Low | $173.49 | $14.55 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | $31.23B | $8.18B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
ZETA trades at $33.03, down 2.1% today but remains near recent highs with strong technical momentum. The company shows robust revenue growth with $1.3B in 2025 and projected $1.6B in 2026, though profitability remains challenged with negative net margins. Recent earnings beats and expanding customer base (197 superscale customers in Q2 2026) support the bullish analyst consensus.
ZETA presents a growth story with expanding AI platform adoption and international expansion, but faces execution risks amid negative cash flow and high valuation multiples. The stock's 75% buy rating from analysts suggests upside potential, though investors should monitor margin improvement and cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
